Chimeric mAbs were less evident ... this class of mAbs has been the main source of antibody-based products entering clinical studies since 1997. Figure 1: Number of mAbs entering clinical studies ...

to bispecific antibodies and chimeric antigen receptors for cell-based therapies. RubrYc’s collaboration model includes options for co-discovery and co-development programs, for out-licensing or ...

Chimeric antigen receptor-T (CAR-T) cell therapy ... (2) These cells are activated using anti-CD3/CD28 antibodies to stimulate their proliferation. (3) Genetic modification of the T cells is performed ...